VELCADE in MALT Lymphoma Pretreated With More Than One Prior Systemic Therapy

Lymphoma, Mucosa-Associated Lymphoid Tissue Clinical Trial

Official title:
Phase II Study of VELCADE in Patients With Extranodal Marginal Zone B-Cell Lymphoma of MALT-Type Pretreated With More Than One Prior Systemic Therapy Regimen (X05142)

Status Terminated

Clinical Trial Summary

The primary objective of this study is to assess the antitumor activity (in terms of overall response rate - ORR - i.e. sum of complete and partial responses) of bortezomib in pretreated MALT lymphomas with more than one prior systemic therapy regimen

Clinical Trial Description

n/a

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Lymphoma
Lymphoma, B-Cell, Marginal Zone
Lymphoma, Mucosa-Associated Lymphoid Tissue

Clinical Trial Details

NCT number	NCT00210392
Study type	Interventional
Source	International Extranodal Lymphoma Study Group (IELSG)
Contact
Status	Terminated
Phase	Phase 2
Start date	July 2005
Completion date	November 2007

View Details

See also
	Status	Clinical Trial	Phase
	Completed	`NCT00210327` - VELCADE in MALT Lymphoma Pretreated With Prior Systemic Therapy	Phase 2
	Completed	`NCT00210353` - Randomized Trial of Chlorambucil Versus Chlorambucil Plus Rituximab Versus Rituximab in MALT Lymphoma	Phase 3